1225601

Doxercalciferol

United States Pharmacopeia (USP) Reference Standard

• 동의어(들): (5Z,7E,22E)-9,10-Secoergosta-5,7,10(19),22-tetraene-1α,3β-diol, (5Z,7E,22E)-9,10-Secoergosta-5,7,10(19),22-tetraene-1,3-diol, 1α-Hydroxyergocalciferol, 1α-Hydroxyvitamin D₂, 1α-OHD2, 1-α-Hydroxyvitamin D2, 1-Hydroxyergocalciferol, TSA 840
• 실험식(Hill 표기법): C₂₈H₄₄O₂
• CAS Number: 54573-75-0
• Molecular Weight: 412.65
• MDL number: MFCD00871065
• UNSPSC 코드: 41116107
• PubChem Substance ID: 329749675
• NACRES: NA.24

속성

• Grade: pharmaceutical primary standard
• API family: doxercalciferol
• 제조업체/상표: USP
• 응용 분야: pharmaceutical (small molecule)
• 형식: neat
• SMILES string: CC(C)[C@@H](C)\C=C\[C@@H](C)[C@H]1CC[C@H]2C(\CCC[C@]12C)=C\C=C3\C[C@@H](O)C[C@H](O)C3=C
• InChI: 1S/C28H44O2/c1-18(2)19(3)9-10-20(4)25-13-14-26-22(8-7-15-28(25,26)6)11-12-23-16-24(29)17-27(30)21(23)5/h9-12,18-20,24-27,29-30H,5,7-8,13-17H2,1-4,6H3/b10-9+,22-11+,23-12-/t19-,20+,24+,25+,26-,27-,28+/m0/s1
• InChI key: HKXBNHCUPKIYDM-CGMHZMFXSA-N
• 유전자 정보: human ... VDR(7421)

설명

일반 설명

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including MSDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.
For further information and support please go to the website of the issuing Pharmacopoeia.

애플리케이션

Doxercalciferol USP reference standard for use in specified quality tests and assays.

Also used to prepare standard, and standard stock solutions for the assay, and impurity analysis in Doxercalciferol by Liquid chromatography in conjunction with UV detector according to the United States Pharmacopeia monograph (USP).

생화학적/생리학적 작용

Doxercalciferol is a Vitamin D2 analogue, a Vitamin D Receptor Activator (VDRA).

Doxercalciferol is a Vitamin D2 analogue, a Vitamin D Receptor Activator (VDRA). Doxercalciferol acts as a pro-hormone, needing 25-hydroxylation in the liver for bioactivation into 1α, 25-hydroxyvitamin D2. Pivotal studies in adults on dialysis have demonstrated control of secondary hyperparathyroidism that is superior to placebo therapy, without undue suppression of 1st IMA-PTH < 300 pg/mL, or occurrences of hypercalcemia. Doxercalciferol has been shown to be effective in controlling secondary hyperparathyroidism of adult patients with CKD stages 3-4.

Doxercalciferol is a vitamin D₂ analog that acts as a pro-hormone, activated in the liver to 1α,25-dihydroxyvitamin D₂.

Doxercalciferol is a vitamin D₂ analog that acts as a pro-hormone, activated in the liver to 1α,25-dihydroxyvitamin D₂. Despite its relatively low affinity for the vitamin D receptor (VDR) (before activation), it is effective at suppressing expression of the parathyroid hormone (PTH) gene, and appears to act through the VDR.

분석 메모

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

기타 정보

Sales restrictions may apply.

안전성 정보

• 픽토그램: GHS06
• 신호어: Danger
• 유해 및 위험 성명서: H300
• 예방조치 성명서: P264 - P270 - P301 + P310 - P405 - P501
• Hazard Classifications: Acute Tox. 1 Oral
• Storage Class Code: 6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials
• WGK: WGK 3
• Flash Point (°F): Not applicable
• Flash Point (°C): Not applicable